MELANOMA (SKIN)
Clinical trials for MELANOMA (SKIN) explained in plain language.
Never miss a new study
Get alerted when new MELANOMA (SKIN) trials appear
Sign up with your email to follow new studies for MELANOMA (SKIN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Four-Week drug blitz tested to stop deadly skin Cancer's comeback
Disease control OngoingThis large study tested whether a short, intense 4-week course of a drug called interferon alfa-2b could help prevent melanoma skin cancer from coming back after it had been surgically removed. It compared the drug treatment to simply watching patients closely (observation) in ov…
Matched conditions: MELANOMA (SKIN)
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New vaccine combo aims to boost Body's fight against advanced skin cancer
Disease control OngoingThis study is testing whether adding one of two experimental cancer vaccines (SCIB1 or iSCIB1+) to standard immunotherapy drugs can help people with advanced, inoperable melanoma. The goal is to see if the vaccines make the standard treatments work better and longer for patients.…
Matched conditions: MELANOMA (SKIN)
Phase: PHASE2 • Sponsor: Scancell Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Smart drug cycling tested for tough skin cancer
Disease control OngoingThis early pilot study is testing whether using a flexible on-and-off schedule for three cancer drugs works better for people with advanced melanoma that has a specific BRAF gene mutation. The drugs combine targeted therapy (encorafenib and binimetinib) that blocks cancer cell gr…
Matched conditions: MELANOMA (SKIN)
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
First human test of novel cancer vaccine begins
Disease control OngoingThis is an early safety study testing a new cancer vaccine called PeptiCRAd-1, given alongside the immunotherapy drug pembrolizumab. It aims to see if this combination is safe and can activate the immune system to fight cancer in patients with advanced solid tumors that have stop…
Matched conditions: MELANOMA (SKIN)
Phase: PHASE1 • Sponsor: Valo Therapeutics Oy • Aim: Disease control
Last updated Mar 03, 2026 14:07 UTC